In The News: School of Integrated Health Sciences
In a new study from the University of Nevada, Las Vegas, researchers confirmed the link between type 2 diabetes and Alzheimer’s disease.
Eisai and Biogen announced that Eisai has initiated a rolling submission to the US Food and Drug Administration (FDA) of a Biologics License Application (BLA) for lecanemab (BAN2401), the company’s investigational anti-amyloid beta (Aß) protofibril antibody, for the treatment of early Alzheimer’s disease (early AD).
Optimistic about the drug’s efficacy, the company has initiated its submission for accelerated FDA approval.
A team of UNLV neuroscientists has strengthened the link between Type II diabetes and Alzheimer's disease.
A team of UNLV neuroscientists has strengthened the link between Type II diabetes and Alzheimer's disease.
A team of neuroscientists at UNLV has reinforced the evidence for a link between type II diabetes and Alzheimer's disease.
A team of neuroscientists from the University of Nevada, Las Vegas-UNLV confirms the link between type II diabetes and Alzheimer's disease.
A team of UNLV neuroscientists has strengthened the link between Type II diabetes and Alzheimer's disease.
A team of UNLV neuroscientists has strengthened the link between Type II diabetes and Alzheimer’s disease.
A team of UNLV neuroscientists has strengthened the link between Type II diabetes and Alzheimer’s disease.
A new program at UNLV is addressing a critical healthcare shortage in the Las Vegas valley.
Dr. Kara Radzak discusses recent updates in sport-related concussion assessment and rehabilitation with Dr. Abigail Bretzin, Dr. Jaclyn Caccese, and Dr. Justin Karr.